Shaping the spectrum - From autoinflammation to autoimmunity

Clinical Immunology

Volumn 165, Issue , 2016, Pages 21-28

  Hedrich, Christian M ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Autoimmunity; Autoinflammation; Inflammation; Psoriasis; SLE; Systemic JIA

Indexed keywords

ADAPTIVE IMMUNITY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; AUTOINFLAMMATORY DISEASE; CLINICAL TRIAL (TOPIC); COMPLEMENT DEFICIENCY; DISEASE ACTIVITY; DISEASE CONTROL; HUMAN; INNATE IMMUNITY; PRIORITY JOURNAL; PSORIASIS; REVIEW; RISK ASSESSMENT; SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; IMMUNOLOGY; INFLAMMATION; JUVENILE RHEUMATOID ARTHRITIS;

ARTHRITIS, JUVENILE; AUTOIMMUNITY; HUMANS; INFLAMMATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; PSORIASIS;

EID: 84960426342     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2016.03.002     Document Type: Review

References (77)

1. Almeida de Jesus A., Goldbach-Mansky R. Monogenic autoinflammatory diseases: concept and clinical manifestations. Clin. Immunol. 2013, 147:155-174.
2. Goldbach-Mansky R., Kastner D.L. Autoinflammation: the prominent role of IL-1 in monogenic autoinflammatory diseases and implications for common illnesses. J. Allergy Clin. Immunol. 2009, 124:1141-1149. quiz 50-1.
3. Masters S.L. Specific inflammasomes in complex diseases. Clin. Immunol. 2013, 147:223-228.
4. Masters S.L. Broadening the definition of autoinflammation. Semin. Immunopathol. 2015, 37:311-312.
5. Sarrabay G., Barat-Houari M., Annakib S., Touitou I. The autoinflammatory diseases: a fashion with blurred boundaries!. Semin. Immunopathol. 2015, 37:359-362.
6. Masters S.L., Simon A., Aksentijevich I., Kastner D.L. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease (*). Annu. Rev. Immunol. 2009, 27:621-668.
7. Hedrich C.M., Tsokos G.C. Bridging the gap between autoinflammation and autoimmunity. Clin. Immunol. 2013, 147:151-154.
8. Simon A.K., Hollander G.A., McMichael A. Evolution of the immune system in humans from infancy to old age. Proceedings Biological Sciences/The Royal Society 2015, 282.
9. Davidson A., Diamond B. Autoimmune diseases. N. Engl. J. Med. 2001, 345:340-350.
10. Hedrich C.M., Bream J.H. Cell type-specific regulation of IL-10 expression in inflammation and disease. Immunol. Res. 2010, 47:185-206.
11. Hofmann S.R., Rosen-Wolff A., Tsokos G.C., Hedrich C.M. Biological properties and regulation of IL-10 related cytokines and their contribution to autoimmune disease and tissue injury. Clin. Immunol. 2012, 143:116-127.
12. McDermott M.F., Aksentijevich I., Galon J., McDermott E.M., Ogunkolade B.W., Centola M., et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999, 97:133-144.
13. McGonagle D., McDermott M.F. A proposed classification of the immunological diseases. PLoS Med. 2006, 3.
14. Canna S.W., Goldbach-Mansky R. New monogenic autoinflammatory diseases-a clinical overview. Semin. Immunopathol. 2015, 37:387-394.
15. Aksentijevich I. Update on genetics and pathogenesis of autoinflammatory diseases: the last 2 years. Semin. Immunopathol. 2015, 37:395-401.
16. Alarcon G.S., McGwin G., Petri M., Ramsey-Goldman R., Fessler B.J., Vila L.M., et al. Time to renal disease and end-stage renal disease in PROFILE: a multiethnic lupus cohort. PLoS Med. 2006, 3.
17. Bruck N., Schnabel A., Hedrich C.M. Current understanding of the pathophysiology of systemic juvenile idiopathic arthritis (sJIA) and target-directed therapeutic approaches. Clin. Immunol. 2015, 159:72-83.
18. Brydges S., Kastner D.L. The systemic autoinflammatory diseases: inborn errors of the innate immune system. Curr. Top. Microbiol. Immunol. 2006, 305:127-160.
19. Behrens E.M., Beukelman T., Gallo L., Spangler J., Rosenkranz M., Arkachaisri T., et al. Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry (PASOJAR). J. Rheumatol. 2008, 35:343-348.
20. Correll C.K., Binstadt B.A. Advances in the pathogenesis and treatment of systemic juvenile idiopathic arthritis. Pediatr. Res. 2014, 75:176-183.
21. Martini A. Systemic juvenile idiopathic arthritis. Autoimmun. Rev. 2012, 12:56-59.
22. Hedrich C.M., Bruck N., Fiebig B., Gahr M. Anakinra: a safe and effective first-line treatment in systemic onset juvenile idiopathic arthritis (SoJIA). Rheumatol. Int. 2012, 32:3525-3530.
23. Nigrovic P.A., Mannion M., Prince F.H., Zeft A., Rabinovich C.E., van Rossum M.A., et al. Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 2011, 63:545-555.
24. Vastert S.J., de Jager W., Noordman B.J., Holzinger D., Kuis W., Prakken B.J., et al. Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study. Arthritis Rheum. 2014, 66:1034-1043.
25. Petty R.E., Southwood T.R., Manners P., Baum J., Glass D.N., Goldenberg J., et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J. Rheumatol. 2004, 31:390-392.
26. Nigrovic P.A. Review: is there a window of opportunity for treatment of systemic juvenile idiopathic arthritis?. Arthritis Rheum. 2014, 66:1405-1413.
27. De Benedetti F., Brunner H.I., Ruperto N., Kenwright A., Wright S., Calvo I., et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N. Engl. J. Med. 2012, 367:2385-2395.
28. Ruperto N., Brunner H.I., Quartier P., Constantin T., Wulffraat N., Horneff G., et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N. Engl. J. Med. 2012, 367:2396-2406.
29. Stock C.J., Ogilvie E.M., Samuel J.M., Fife M., Lewis C.M., Woo P. Comprehensive association study of genetic variants in the IL-1 gene family in systemic juvenile idiopathic arthritis. Genes Immun. 2008, 9:349-357.
30. Fishman D., Faulds G., Jeffery R., Mohamed-Ali V., Yudkin J.S., Humphries S., et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J. Clin. Invest. 1998, 102:1369-1376.
31. Ogilvie E.M., Fife M.S., Thompson S.D., Twine N., Tsoras M., Moroldo M., et al. The -174G allele of the interleukin-6 gene confers susceptibility to systemic arthritis in children: a multicenter study using simplex and multiplex juvenile idiopathic arthritis families. Arthritis Rheum. 2003, 48:3202-3206.
32. Fife M.S., Gutierrez A., Ogilvie E.M., Stock C.J., Samuel J.M., Thomson W., et al. Novel IL10 gene family associations with systemic juvenile idiopathic arthritis. Arthritis Res. Ther. 2006, 8:R148.
33. Kaalla M.J., Broadaway K.A., Rohani-Pichavant M., Conneely K.N., Whiting A., Ponder L., et al. Meta-analysis confirms association between TNFA-G238A variant and JIA, and between PTPN22-C1858T variant and oligoarticular, RF-polyarticular and RF-positive polyarticular JIA. Pediatric Rheumatology Online Journal 2013, 11:40.
34. De Benedetti F., Meazza C., Vivarelli M., Rossi F., Pistorio A., Lamb R., et al. Functional and prognostic relevance of the -173 polymorphism of the macrophage migration inhibitory factor gene in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2003, 48:1398-1407.
35. Donn R.P., Shelley E., Ollier W.E., Thomson W., British Paediatric Rheumatology Study G A novel 5'-flanking region polymorphism of macrophage migration inhibitory factor is associated with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2001, 44:1782-1785.
36. Moller J.C., Paul D., Ganser G., Range U., Gahr M., Kelsch R., et al. IL10 promoter polymorphisms are associated with systemic onset juvenile idiopathic arthritis (SoJIA). Clin. Exp. Rheumatol. 2010, 28:912-918.
37. Wakil S.M., Monies D.M., Abouelhoda M., Al-Tassan N., Al-Dusery H., Naim E.A., et al. Association of a mutation in LACC1 with a monogenic form of systemic juvenile idiopathic arthritis. Arthritis Rheum. 2015, 67:288-295.
38. Boehncke W.H., Schon M.P. Psoriasis. Lancet 2015, 386:983-994.
39. Christophers E., Metzler G., Rocken M. Bimodal immune activation in psoriasis. Br. J. Dermatol. 2014, 170:59-65.
40. Harden J.L., Krueger J.G., Bowcock A.M. The immunogenetics of psoriasis: a comprehensive review. J. Autoimmun. 2015, 64:66-73.
41. Harden J.L., Lewis S.M., Pierson K.C., Suarez-Farinas M., Lentini T., Ortenzio F.S., et al. CARD14 expression in dermal endothelial cells in psoriasis. PLoS One 2014, 9.
42. Jordan C.T., Cao L., Roberson E.D., Duan S., Helms C.A., Nair R.P., et al. Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis. Am. J. Hum. Genet. 2012, 90:796-808.
43. Jordan C.T., Cao L., Roberson E.D., Pierson K.C., Yang C.F., Joyce C.E., et al. PSORS2 is due to mutations in CARD14. Am. J. Hum. Genet. 2012, 90:784-795.
44. Zilberman-Rudenko J., Shawver L.M., Wessel A.W., Luo Y., Pelletier M., Tsai W.L., et al. Recruitment of A20 by the C-terminal domain of NEMO suppresses NF-kappaB activation and autoinflammatory disease. Proc. Natl. Acad. Sci. U. S. A. 2016, 113:1612-1617.
45. Zhou Q., Wang H., Schwartz D.M., Stoffels M., Park Y.H., Zhang Y., et al. Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease. Nat. Genet. 2016, 48:67-73.
46. Diani M., Altomare G., Reali E. T cell responses in psoriasis and psoriatic arthritis. Autoimmun. Rev. 2015, 14:286-292.
47. Hedrich C.M., Hahn G., Girschick H.J., Morbach H. A clinical and pathomechanistic profile of chronic nonbacterial osteomyelitis/chronic recurrent multifocal osteomyelitis and challenges facing the field. Expert Rev. Clin. Immunol. 2013, 9:845-854.
48. Hedrich C.M., Hofmann S.R., Pablik J., Morbach H., Girschick H.J. Autoinflammatory bone disorders with special focus on chronic recurrent multifocal osteomyelitis (CRMO). Pediatric Rheumatology Online Journal 2013, 11:47.
49. Morbach H., Hedrich C.M., Beer M., Girschick H.J. Autoinflammatory bone disorders. Clin. Immunol. 2013, 147:185-196.
50. Lande R., Botti E., Jandus C., Dojcinovic D., Fanelli G., Conrad C., et al. The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis. Nat. Commun. 2014, 5:5621.
51. Lande R., Botti E., Jandus C., Dojcinovic D., Fanelli G., Conrad C., et al. Corrigendum: the antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis. Nat. Commun. 2015, 6:6595.
52. Crispin J.C., Hedrich C.M., Tsokos G.C. Gene-function studies in systemic lupus erythematosus. Nat. Rev. Rheumatol. 2013, 9:476-484.
53. Tsokos G.C. Systemic lupus erythematosus. N. Engl. J. Med. 2011, 365:2110-2121.
54. Ablasser A., Hertrich C., Wassermann R., Hornung V. Nucleic acid driven sterile inflammation. Clin. Immunol. 2013, 147:207-215.
55. Cook H.T., Botto M. Mechanisms of disease: the complement system and the pathogenesis of systemic lupus erythematosus. Nat. Clin. Pract. Rheumatol. 2006, 2:330-337.
56. Atkinson J.P. Complement deficiency: predisposing factor to autoimmune syndromes. Clin. Exp. Rheumatol. 1989, 7(Suppl. 3):S95-101.
57. Ptacek T., Li X., Kelley J.M., Edberg J.C. Copy number variants in genetic susceptibility and severity of systemic lupus erythematosus. Cytogenet. Genome Res. 2008, 123:142-147.
58. Yang Y., Chung E.K., Wu Y.L., Savelli S.L., Nagaraja H.N., Zhou B., et al. Gene copy-number variation and associated polymorphisms of complement component C4 in human systemic lupus erythematosus (SLE): low copy number is a risk factor for and high copy number is a protective factor against SLE susceptibility in European Americans. Am. J. Hum. Genet. 2007, 80:1037-1054.
59. Crow Y.J. Type I interferonopathies: mendelian type I interferon up-regulation. Curr. Opin. Immunol. 2015, 32:7-12.
60. International Consortium for Systemic Lupus Erythematosus G, Harley J.B., Alarcon-Riquelme M.E., Criswell L.A., Jacob C.O., Kimberly R.P., et al. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat. Genet. 2008, 40:204-210.
61. Hedrich C.M., Fiebig B., Hauck F.H., Sallmann S., Hahn G., Pfeiffer C., et al. Chilblain lupus erythematosus-a review of literature. Clin. Rheumatol. 2008, 27:949-954.
62. Al-Mayouf S.M., Sunker A., Abdwani R., Abrawi S.A., Almurshedi F., Alhashmi N., et al. Loss-of-function variant in DNASE1L3 causes a familial form of systemic lupus erythematosus. Nat. Genet. 2011, 43:1186-1188.
63. Lee-Kirsch M.A., Gong M., Chowdhury D., Senenko L., Engel K., Lee Y.A., et al. Mutations in the gene encoding the 3'-5' DNA exonuclease TREX1 are associated with systemic lupus erythematosus. Nat. Genet. 2007, 39:1065-1067.
64. Namjou B., Kothari P.H., Kelly J.A., Glenn S.B., Ojwang J.O., Adler A., et al. Evaluation of the TREX1 gene in a large multi-ancestral lupus cohort. Genes Immun. 2011, 12:270-279.
65. Crow Y.J., Chase D.S., Lowenstein Schmidt J., Szynkiewicz M., Forte G.M., Gornall H.L., et al. Characterization of human disease phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR, and IFIH1. American Journal of Medical Genetics Part A 2015, 167A:296-312.
66. Rice G.I., del Toro Duany Y., Jenkinson E.M., Forte G.M., Anderson B.H., Ariaudo G., et al. Gain-of-function mutations in IFIH1 cause a spectrum of human disease phenotypes associated with upregulated type I interferon signaling. Nat. Genet. 2014, 46:503-509.
67. Jeremiah N., Neven B., Gentili M., Callebaut I., Maschalidi S., Stolzenberg M.C., et al. Inherited STING-activating mutation underlies a familial inflammatory syndrome with lupus-like manifestations. J. Clin. Invest. 2014, 124:5516-5520.
68. Liu Y., Jesus A.A., Marrero B., Yang D., Ramsey S.E., Montealegre Sanchez G.A., et al. Activated STING in a vascular and pulmonary syndrome. N. Engl. J. Med. 2014, 371:507-518.
69. Crow M.K. Advances in understanding the role of type I interferons in systemic lupus erythematosus. Curr. Opin. Rheumatol. 2014, 26:467-474.
70. Trinchieri G. Type I interferon: friend or foe?. J. Exp. Med. 2010, 207:2053-2063.
71. dos Santos B.P., Valverde J.V., Rohr P., Monticielo O.A., Brenol J.C., Xavier R.M., et al. TLR7/8/9 polymorphisms and their associations in systemic lupus erythematosus patients from southern Brazil. Lupus 2012, 21:302-309.
72. Enevold C., Nielsen C.H., Jacobsen R.S., Hermansen M.L., Molbo D., Avlund K., et al. Single nucleotide polymorphisms in genes encoding toll-like receptors 7, 8 and 9 in Danish patients with systemic lupus erythematosus. Mol. Biol. Rep. 2014, 41:5755-5763.
73. Tian J., Ma Y., Li J., Cen H., Wang D.G., Feng C.C., et al. The TLR7 7926A>G polymorphism is associated with susceptibility to systemic lupus erythematosus. Molecular Medicine Reports 2012, 6:105-110.
74. Aitman T.J., Dong R., Vyse T.J., Norsworthy P.J., Johnson M.D., Smith J., et al. Copy number polymorphism in Fcgr3 predisposes to glomerulonephritis in rats and humans. Nature 2006, 439:851-855.
75. Brown E.E., Edberg J.C., Kimberly R.P. Fc receptor genes and the systemic lupus erythematosus diathesis. Autoimmunity 2007, 40:567-581.
76. Chen K., Nishi H., Travers R., Tsuboi N., Martinod K., Wagner D.D., et al. Endocytosis of soluble immune complexes leads to their clearance by FcgammaRIIIB but induces neutrophil extracellular traps via FcgammaRIIA in vivo. Blood 2012, 120:4421-4431.
77. Fanciulli M., Norsworthy P.J., Petretto E., Dong R., Harper L., Kamesh L., et al. FCGR3B copy number variation is associated with susceptibility to systemic, but not organ-specific, autoimmunity. Nat. Genet. 2007, 39:721-723.